Skip to main content
The Egyptian Heart Journal
Fig. 6 | The Egyptian Heart Journal

Fig. 6

From: Is triple antithrombotic therapy a safe option in patients with AF who receive drug-eluting stents?: a review article

Fig. 6

PIONEER AF-PCI (2016) trial: Primary outcomes of major bleeding, Significant high bleeding rates in the TAT group compared to DAT. Group 1 = rivaroxaban 10–15 mg daily + P2Y12 inhibitor, Group 2 = Riva. 2.5 mg BID + DAP, Group 3 = VKA + DAPT [33]. https://doi.org/10.1056/NEJMoa1611594

Back to article page